Skip to main content
logo
Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.544
-0.026 (-1.66%)
Sep 12, 2025, 4:00 PM EDT - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Novel Synthetic Lethality-based Cancer Therapeutics
1.50M
Log In
Novel Synthetic Lethality-based Cancer Therapeutics Growth
157.63%
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Sweden
1.50M
Log In
Sweden Growth
157.63%
Log In